- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 68
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myositis Associated Interstitial Lund Disease (MA-ILD)
- Interventions
- Nintedanib, Placebo, Standard of Care
- Drug
- Lead sponsor
- Rohit Aggarwal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
- Conditions
- Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis
- Interventions
- Baricitinib 2 MG [Olumiant], Methotrexate, Azathioprine, Mycophenolate
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
- Interventions
- baricitinib
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alopecia Areata
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more
- Conditions
- Central Centrifugal Cicatricial Alopecia
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Raven Clinical Research
- Network
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Marriottsville, Maryland • Fairfax, Virginia • McLean, Virginia + 1 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- targeted synthetic DMARD class, non-TNFi-biologic class
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 924 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 48
- States / cities
- Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more
- Conditions
- Depressive Symptoms, Cognitive Symptom
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 30 Years to 55 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Aicardi Goutieres Syndrome
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Adeline Vanderver, MD
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Interventions
- Placebo, Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 18
- States / cities
- Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more
- Conditions
- Covid19, Corona Virus Infection
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Detroit, Michigan • Cleveland, Ohio
- Conditions
- Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Baricitinib, Hydroxychloroquine, Placebo Administration
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Santa Barbara, California • Tallahassee, Florida • Iowa City, Iowa + 4 more
- Conditions
- Atopic Dermatitis
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more
- Conditions
- COVID-19
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- COVID-19
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Adalimumab, Baricitinib, Methotrexate, Adalimumab Placebo, Baricitinib Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 45
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus
- Interventions
- Baricitinib 4 milligram Oral Tablet
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Dermatomyositis
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy Volunteers
- Interventions
- LY3009104
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Rheumatoid Arthritis
- Interventions
- INCB028050, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 38 more
- Conditions
- COVID-19
- Interventions
- Baricitinib, Dexamethasone, Placebo, Remdesivir
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Fresno, California • La Jolla, California + 50 more